Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments
- Women between 18 and 75 years old
- People whose doctors expect them to live for at least 12 weeks
- People whose major organs (such as heart, liver, and kidneys) are functioning normally
- Women who could potentially become pregnant must have a negative pregnancy blood test within 7 days before the first dose, and must not be breastfeeding
- Women must agree to use contraception from the time of signing the consent form until 7 months after the last dose of the study drug
Who may not be able to join:
- People who have had, or currently have, another type of cancer (separate from the one being studied)
- People with severe bone damage caused by cancer that has spread to the bones
- People who have an active autoimmune disease, or a history of autoimmune disease that could come back
- People who currently have active tuberculosis
- People with poorly controlled or serious heart or blood vessel disease
- People who have had a blood clot in a vein or artery within the 6 months before the first dose
- People who have had a bowel blockage, or symptoms suggesting a bowel blockage, within the 6 months before the first dose
- People who have had a serious infection within 1 month before the first dose
- People with a history of immune system deficiency
- People whom the trial investigator believes may have other health or personal factors that could affect the study results or require them to leave the study early (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0518-82342973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Grade≥3 drug-related adverse events (TRAEs).; Grade≥3 drug-related serious adverse events (TRAEs).; Objective response rate (ORR).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.